hotspot -WSS

hotspot

author：comprehensive 2025-09-29 14:18:19 - browse：734

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： CDC overhauls leadership of center that led response to Covid

hotspot

WSS

Kim Kardashian sparks debate on benefits of full

Flu vaccine offering decent levels of protection this winter, new data show

Some of the ways extreme heat will change life as we know it

Kenai launches with $82 million for Parkinson’s stem cell therapy

Faced with fears of OxyContin misuse, sales reps touted its safety

Medical device lobby: We're tired of waiting on Medicare coverage

Wikipedia

hotspot

focus

Apple is now the first public company to be valued at $3 trillion

Biotech companies concerned about China biosecurity crackdown

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Medical leaders decry Supreme Court decision on affirmative action

Congress gives doctors Medicare pay bump

Guidelines to prevent youth baseball injuries need more muscle

In search for therapies for solid tumors, companies turn to claudin

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medical device lobby: We're tired of waiting on Medicare coverage

explore

The history of OxyContin, told through Purdue Pharma documents

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

RaDonda Vaught to speak at CommonSpirit event on patient safety

Novo acquires Inversago for up to $1 billion

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Where are patients getting their prescriptions for GLP

hotspot

focus

focus

focus